Which statement is true about the use of ipratropium?

Ipratropium is an anticholinergic bronchodilator often used in the management of respiratory conditions like chronic obstructive pulmonary disease (COPD) and asthma. Its primary action is to relax the muscles around the airways, leading to bronchodilation. The statement about its use in non-emergency situations is accurate because ipratropium is typically administered for long-term management rather than immediate relief. It is often combined with short-acting beta-agonists for control of symptoms but is not classified as a rescue medication.

The other statements do not hold true in the context of ipratropium's usage or effects. It does have potential side effects, including dry mouth and respiratory infections. Additionally, it is generally not recommended to use ipratropium with other anticholinergics unless specifically directed by a healthcare provider, as this could lead to an increased risk of adverse effects. Furthermore, ipratropium does not encourage mucus production; rather, it helps reduce bronchial secretions. Thus, the preference for ipratropium in non-emergency situations is rooted in its role as a maintenance therapy rather than for acute relief.